FREE subscriptions for doctors and students... click here
You have 3 more open access pages.

The main results of the IFNB Multiple Sclerosis Study Group trial were:

  • the high dose of interferon beta-1b resulted in a significant reduction in disease burden on MRI scans as compared to placebo

  • the annual relapse rate was significantly lower in the treatment arms:
    • 1.12 in the placebo group
    • 0.96 in the 1.6 MIU group
    • 0.78 in the 8 MIU group
    • the relapse rate was lower in patients on treatment who did not develop neutralising antibodies to interferon beta-1b

  • the was a non-significant reduction in confirmed progression of disability in the treatment arm

Last reviewed 01/2018